Scarantino Charles W, Prestidge Bradley R, Anscher Mitchel S, Ferree Carolyn R, Kearns William T, Black Robert D, Bolick Natasha G, Beyer Gloria P
Sicel Technologies Inc., Morrisville, NC, USA.
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):597-604. doi: 10.1016/j.ijrobp.2008.05.058.
Report the results of using a permanently implantable dosimeter in radiation therapy: determine specific adverse events, degree of migration, and acquire dose measurements during treatment to determine difference between expected and measured dose.
The Dose Verification System is a wireless, permanently implantable metal-oxide semiconductor field-effect transistor dosimeter using a bidirectional antenna for power and data transfer. The study cohort includes 36 breast (33 patients received two devices) and 29 prostate (21 patients received two devices) cancer patients. A total of 1,783 and 1,749 daily dose measurements were obtained on breast and prostate patients, respectively. The measurements were compared with the planned expected dose. Biweekly computed tomography scans were obtained to evaluate migration and the National Cancer Institute's Common Toxicity Criteria, version 3, was used to evaluate adverse events.
Only Grade I/II adverse events of pain and bleeding were noted. There were only four instances of dosimeter migration of >5 mm from known factors. A deviation of > or =7% in cumulative dose was noted in 7 of 36 (19%) for breast cancer patients. In prostate cancer patients, a > or =7% deviation was noted in 6 of 29 (21%) and 8 of 19 (42%) during initial and boost irradiation, respectively. The two patterns of dose deviation were random and systematic. Some causes for these differences could involve organ movement, patient movement, or treatment plan considerations.
The Dose Verification System was not associated with significant adverse events or migration. The dosimeter can measure dose in situ on a daily basis. The accuracy and utility of the dose verification system complements current image-guided radiation therapy and intensity-modulated radiation therapy techniques.
报告在放射治疗中使用永久性植入式剂量仪的结果：确定特定不良事件、迁移程度，并在治疗期间获取剂量测量值以确定预期剂量与测量剂量之间的差异。
剂量验证系统是一种无线、永久性植入式金属氧化物半导体场效应晶体管剂量仪，使用双向天线进行能量和数据传输。研究队列包括36例乳腺癌患者（33例患者接受了两个装置）和29例前列腺癌患者（21例患者接受了两个装置）。分别在乳腺癌和前列腺癌患者中获得了总共1783次和1749次每日剂量测量值。将测量结果与计划的预期剂量进行比较。每两周进行一次计算机断层扫描以评估迁移情况，并使用美国国立癌症研究所的第3版常见毒性标准来评估不良事件。
仅记录到I/II级疼痛和出血等不良事件。由于已知因素，剂量仪迁移>5 mm的情况仅出现了4例。在36例乳腺癌患者中，有7例（19%）的累积剂量偏差>或=7%。在前列腺癌患者中，初始照射和增强照射期间分别有29例中的6例（21%）和19例中的8例（42%）出现>或=7%的偏差。剂量偏差的两种模式是随机的和系统性的。这些差异的一些原因可能涉及器官移动、患者移动或治疗计划考虑因素。
剂量验证系统与重大不良事件或迁移无关。该剂量仪可以每天原位测量剂量。剂量验证系统的准确性和实用性补充了当前的图像引导放射治疗和调强放射治疗技术。
